Rare variants and HLA haplotypes associated in patients with neuromyelitis optica spectrum disorders
暂无分享,去创建一个
Mark D. Messina | Yufeng Shen | D. Keskin | V. Brusic | V. Jeganathan | P. Jindra | S. Najjar | Jiayao Wang | J. Drulovic | E. Yunis | M. Gudesblatt | Akemi J. Tanaka | I. Tabansky | A. Harel | I. Dujmovic | S. Mader | V. Nursey | M. Funaro | Guanglan Zhang | K. Blitz | Joel N. H. Stern | Alejandra K. King | T. Deangelis | Maya Shabbir | William DeGouvia | Micheline Laurent | A. King | Asaff Harel | Mark Gudesblatt
[1] B. Feng,et al. Multi-Level Analyses of Genome-Wide Association Study to Reveal Significant Risk Genes and Pathways in Neuromyelitis Optica Spectrum Disorder , 2021, Frontiers in Genetics.
[2] J. Shendure,et al. CADD-Splice—improving genome-wide variant effect prediction using deep learning-derived splice scores , 2021, Genome Medicine.
[3] C. Vasconcelos,et al. Neuromyelitis optica is an HLA associated disease different from Multiple Sclerosis: a systematic review with meta-analysis , 2021, Scientific reports.
[4] J. Kira,et al. Genetic factors for susceptibility to and manifestations of neuromyelitis optica , 2020, Annals of clinical and translational neurology.
[5] E. Meinl,et al. Novel insights into pathophysiology and therapeutic possibilities reveal further differences between AQP4-IgG- and MOG-IgG-associated diseases. , 2020, Current opinion in neurology.
[6] M. Daly,et al. Exome sequencing in schizophrenia-affected parent-offspring trios reveals risk conferred by protein-coding de novo mutations , 2019, Nature Neuroscience.
[7] Thawfeek M. Varusai,et al. The reactome pathway knowledgebase , 2019, Nucleic Acids Res..
[8] K. Fujihara,et al. Circulating AQP4-specific auto-antibodies alone can induce neuromyelitis optica spectrum disorder in the rat , 2018, Acta Neuropathologica.
[9] M. Reindl,et al. Myelin oligodendrocyte glycoprotein antibodies in neurological disease , 2018, Nature Reviews Neurology.
[10] R. Hampson,et al. Fibronectin Produced by Cerebral Endothelial and Vascular Smooth Muscle Cells Contributes to Perivascular Extracellular Matrix in Late-Delayed Radiation-Induced Brain Injury , 2018, Radiation Research.
[11] J. Greenbaum,et al. Improved methods for predicting peptide binding affinity to MHC class II molecules , 2018, Immunology.
[12] Robert E Handsaker,et al. A whole-genome sequence study identifies genetic risk factors for neuromyelitis optica , 2018, Nature Communications.
[13] Jinyu Wu,et al. Identification of de novo germline mutations and causal genes for sporadic diseases using trio‐based whole‐exome/genome sequencing , 2018, Biological reviews of the Cambridge Philosophical Society.
[14] H. Lassmann,et al. Mechanisms for lesion localization in neuromyelitis optica spectrum disorders , 2018, Current opinion in neurology.
[15] J. Granados,et al. Neuromyelitis Optica (NMO IgG+) and Genetic Susceptibility, Potential Ethnic Influences. , 2018, Central nervous system agents in medicinal chemistry.
[16] V. Sutton,et al. Mutations in Fibronectin Cause a Subtype of Spondylometaphyseal Dysplasia with "Corner Fractures". , 2017, American journal of human genetics.
[17] Hoang T. Nguyen,et al. Integrated Bayesian analysis of rare exonic variants to identify risk genes for schizophrenia and neurodevelopmental disorders , 2017, bioRxiv.
[18] B. Weinshenker,et al. Neuromyelitis Spectrum Disorders , 2017, Mayo Clinic proceedings.
[19] B. Weinshenker,et al. Neuromyelitis optica spectrum disorder diagnostic criteria: Sensitivity and specificity are both important , 2017, Multiple sclerosis.
[20] F. Paul,et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin , 2016, Journal of Neuroinflammation.
[21] Trevor Hastie,et al. REVEL: An Ensemble Method for Predicting the Pathogenicity of Rare Missense Variants. , 2016, American journal of human genetics.
[22] D. Conrad,et al. Genomewide significance testing of variation from single case exomes , 2016, Nature Genetics.
[23] K. Fujihara,et al. Aquaporin 4-specific T cells and NMO-IgG cause primary retinal damage in experimental NMO/SD , 2016, Acta neuropathologica communications.
[24] V. Majithia,et al. Neuromyelitis Optica (Devic’s Syndrome): an Appraisal , 2016, Current Rheumatology Reports.
[25] T. Ben-Hur,et al. Increased occurrence of anti-AQP4 seropositivity and unique HLA Class II associations with neuromyelitis optica (NMO), among Muslim Arabs in Israel , 2016, Journal of Neuroimmunology.
[26] Morten Nielsen,et al. Gapped sequence alignment using artificial neural networks: application to the MHC class I system , 2016, Bioinform..
[27] James Y. Zou. Analysis of protein-coding genetic variation in 60,706 humans , 2015, Nature.
[28] K. Fujihara,et al. Highly encephalitogenic aquaporin 4-specific T cells and NMO-IgG jointly orchestrate lesion location and tissue damage in the CNS , 2015, Acta Neuropathologica.
[29] J. Tolmie,et al. Haploinsufficiency of the NOTCH1 Receptor as a Cause of Adams–Oliver Syndrome With Variable Cardiac Anomalies , 2015, Circulation. Cardiovascular genetics.
[30] A. Traboulsee,et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders , 2015, Neurology.
[31] L. Kappos,et al. Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype , 2015, Journal of Neuroinflammation.
[32] Bale,et al. Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.
[33] John T. Chang,et al. A gp130–Src–YAP module links inflammation to epithelial regeneration , 2015, Nature.
[34] Andrew R. Jones,et al. Allele frequency net 2015 update: new features for HLA epitopes, KIR and disease and HLA adverse drug reaction associations , 2014, Nucleic Acids Res..
[35] K. Matsushima,et al. CCR4 and its ligands: from bench to bedside. , 2015, International immunology.
[36] M. Papadopoulos,et al. Treatment of neuromyelitis optica: state-of-the-art and emerging therapies , 2014, Nature Reviews Neurology.
[37] D. Popadic,et al. HLA-A, -B, -C, -DRB1 and -DQB1 allele and haplotype frequencies in the Serbian population. , 2014, Human immunology.
[38] M. Mori,et al. Neuromyelitis optica: Concept, immunology and treatment , 2014, Journal of Clinical Neuroscience.
[39] Y. Itoyama,et al. The Pathology of an Autoimmune Astrocytopathy: Lessons Learned from Neuromyelitis Optica , 2014, Brain pathology.
[40] A. Wu,et al. The complement and immunoglobulin levels in NMO patients , 2014, Neurological Sciences.
[41] K. Fujihara,et al. T cell-activation in neuromyelitis optica lesions plays a role in their formation , 2013, Acta neuropathologica communications.
[42] S. Iida,et al. Stevens–Johnson Syndrome associated with mogamulizumab treatment of adult T‐cell leukemia / lymphoma , 2013, Cancer science.
[43] Edward Y. Chen,et al. Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool , 2013, BMC Bioinformatics.
[44] S. Jarius,et al. The expanding range of autoimmune disorders of the nervous system , 2013, The Lancet Neurology.
[45] R. Herndon,et al. Differentiation of neuromyelitis optica from multiple sclerosis on spinal magnetic resonance imaging. , 2012, International journal of MS care.
[46] P. Evans,et al. Bin2 Is a Membrane Sculpting N-BAR Protein That Influences Leucocyte Podosomes, Motility and Phagocytosis , 2012, PloS one.
[47] J. Miller,et al. Predicting the Functional Effect of Amino Acid Substitutions and Indels , 2012, PloS one.
[48] J. Kira,et al. Distinct genetic and infectious profiles in Japanese neuromyelitis optica patients according to anti-aquaporin 4 antibody status , 2012, Journal of Neurology, Neurosurgery & Psychiatry.
[49] Jacqueline A Palace,et al. Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype , 2012, Neurology.
[50] D. Wingerchuk,et al. Epidemiology of neuromyelitis optica in the United States: a multicenter analysis. , 2012, Archives of neurology.
[51] M. Papadopoulos,et al. Aquaporin 4 and neuromyelitis optica , 2012, The Lancet Neurology.
[52] H. Kim,et al. Clinical spectrum of CNS aquaporin-4 autoimmunity , 2012, Neurology.
[53] A. Verkman,et al. Complement-dependent Cytotoxicity in Neuromyelitis Optica Requires Aquaporin-4 Protein Assembly in Orthogonal Arrays* , 2012, The Journal of Biological Chemistry.
[54] Jacqueline Palace,et al. Serologic diagnosis of NMO , 2012, Neurology.
[55] K. Kyvik,et al. HLA, PTPN22 and PD-1 associations as markers of autoimmunity in neuromyelitis optica , 2012, Multiple sclerosis.
[56] A. Lutterotti,et al. Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders , 2011, Journal of Neuroinflammation.
[57] R. Gibbs,et al. Exome Sequencing of Head and Neck Squamous Cell Carcinoma Reveals Inactivating Mutations in NOTCH1 , 2011, Science.
[58] A. McKenna,et al. The Mutational Landscape of Head and Neck Squamous Cell Carcinoma , 2011, Science.
[59] M. DePristo,et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data , 2011, Nature Genetics.
[60] P. Visscher,et al. GCTA: a tool for genome-wide complex trait analysis. , 2011, American journal of human genetics.
[61] S. Olindo,et al. Different HLA class II (DRB1 and DQB1) alleles determine either susceptibility or resistance to NMO and multiple sclerosis among the French Afro-Caribbean population , 2011, Multiple sclerosis.
[62] P. Villoslada,et al. [HLA-DRB1 typing in Caucasians patients with neuromyelitis optica]. , 2011, Revista de neurologia.
[63] J. Parratt,et al. Neuromyelitis optica: a demyelinating disease characterized by acute destruction and regeneration of perivascular astrocytes , 2010, Multiple sclerosis.
[64] J. Honnorat,et al. Oligodendrocytes are damaged by neuromyelitis optica immunoglobulin G via astrocyte injury. , 2010, Brain : a journal of neurology.
[65] X. Montalban,et al. EFNS guidelines on diagnosis and management of neuromyelitis optica , 2010, European journal of neurology.
[66] H. Hakonarson,et al. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data , 2010, Nucleic acids research.
[67] Brigitte Wildemann,et al. AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance , 2010, Nature Reviews Neurology.
[68] A. Lutterotti,et al. Patterns of Antibody Binding to Aquaporin-4 Isoforms in Neuromyelitis Optica , 2010, PloS one.
[69] Uthaman Gowthaman,et al. Evaluation of different generic in silico methods for predicting HLA class I binding peptide vaccine candidates using a reverse approach , 2010, Amino Acids.
[70] E. Donadi,et al. HLA-DRB association in neuromyelitis optica is different from that observed in multiple sclerosis , 2010, Multiple sclerosis.
[71] D. Wingerchuk. Neuromyelitis optica: Effect of gender , 2009, Journal of the Neurological Sciences.
[72] Y. Blanco,et al. Cytotoxic effect of neuromyelitis optica antibody (NMO-IgG) to astrocytes: An in vitro study , 2009, Journal of Neuroimmunology.
[73] V. Lennon,et al. Prediction of neuromyelitis optica attack severity by quantitation of complement-mediated injury to aquaporin-4-expressing cells. , 2009, Archives of neurology.
[74] B. Ferry,et al. A Novel Mutation in a Patient with a Deficiency of the Eighth Component of Complement Associated with Recurrent Meningococcal Meningitis , 2009, Journal of Clinical Immunology.
[75] Rebecca A Robbins,et al. Crystal structure of human aquaporin 4 at 1.8 Å and its mechanism of conductance , 2009, Proceedings of the National Academy of Sciences.
[76] P. Vermersch,et al. Is neuromyelitis optica associated with human leukocyte antigen? , 2009, Multiple sclerosis.
[77] J. Kurtzke,et al. An epidemiological study of neuromyelitis optica in Cuba , 2009, Journal of Neurology.
[78] Vladimir Brusic,et al. Evaluation of MHC-II peptide binding prediction servers: applications for vaccine research , 2008, BMC Bioinformatics.
[79] G. Remuzzi,et al. Mutations in FN1 cause glomerulopathy with fibronectin deposits , 2008, Proceedings of the National Academy of Sciences.
[80] F. Paul,et al. Revised diagnostic criteria for neuromyelitis optica—incorporation of NMO-IgG status , 2007, Nature Clinical Practice Neurology.
[81] J. Parisi,et al. Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. , 2007, Brain : a journal of neurology.
[82] D. Reich,et al. Principal components analysis corrects for stratification in genome-wide association studies , 2006, Nature Genetics.
[83] Bernard de Bono,et al. IRIS: a database surveying known human immune system genes. , 2005, Genomics.
[84] Ichiro Nakashima,et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis , 2004, The Lancet.
[85] J. Kutok,et al. Notch Oncoproteins Depend on γ-Secretase/Presenilin Activity for Processing and Function* , 2004, Journal of Biological Chemistry.
[86] Massimo Filippi,et al. Clinical characteristics, course and prognosis of relapsing Devic’s Neuromyelitis Optica , 2004, Journal of Neurology.
[87] O. Lund,et al. novel sequence representations Reliable prediction of T-cell epitopes using neural networks with , 2003 .
[88] Y. Saeki,et al. A Point Mutation of Tyr-759 in Interleukin 6 Family Cytokine Receptor Subunit gp130 Causes Autoimmune Arthritis , 2002, The Journal of experimental medicine.
[89] Sergio Romagnani,et al. Macrophage-Derived Chemokine and EBI1-Ligand Chemokine Attract Human Thymocytes in Different Stage of Development and Are Produced by Distinct Subsets of Medullary Epithelial Cells: Possible Implications for Negative Selection1 , 2000, The Journal of Immunology.
[90] S. Wiese,et al. Developmental Requirement of gp130 Signaling in Neuronal Survival and Astrocyte Differentiation , 1999, The Journal of Neuroscience.
[91] Don C. Wiley,et al. Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide , 1994, Nature.
[92] P. Schneider,et al. Genetic basis of human complement C8 beta deficiency. , 1993, Journal of immunology.
[93] W. Sly,et al. Mutational analysis of a patient with mucopolysaccharidosis type VII, and identification of pseudogenes. , 1993, American journal of human genetics.
[94] W. Sly,et al. Beta glucuronidase deficiency: report of clinical, radiologic, and biochemical features of a new mucopolysaccharidosis. , 1973, The Journal of pediatrics.